Acciones Evotec SE Other OTC
Acciones
EVTCY
US30050E1055
Biotecnología e investigación médica
Ventas 2024 * | 881 M 958 M | Ventas 2025 * | 1036,69 M 1126,59 M | Capitalización | 1601,83 M 1740,73 M |
---|---|---|---|---|---|
Resultado Neto 2024 * | -27 M -29,34 M | Resultado Neto 2025 * | 32 M 34,77 M | VE / Ventas 2024 * | 2,12 x |
Deuda neta 2024 * | 269 M 292 M | Deuda neta 2025 * | 235 M 255 M | VE / Ventas 2025 * | 1,77 x |
P/E ratio 2024 * |
-60,9
x | P/E ratio 2025 * |
33,7
x | Empleados | - |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 90,64 % |
Último transcript sobre Evotec SE
Directores | Puesto | Edad | Desde |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19/06/19 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 07/02/23 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 01/05/12 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19/06/19 |
Roland Sackers
BRD | Director/Board Member | 56 | 19/06/19 |
Chairman | 63 | 17/06/14 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+48,64 % | 56,65 mil M | |
-6,44 % | 39,44 mil M | |
+40,29 % | 39,03 mil M | |
-11,17 % | 26,86 mil M | |
+14,28 % | 26,75 mil M | |
-21,40 % | 19,03 mil M | |
+0,96 % | 12,28 mil M | |
+25,64 % | 12,26 mil M | |
+27,04 % | 12,04 mil M |